Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 6Stomach Neoplasms 5Lung Neoplasms 4Neoplasm Metastasis 2Urinary Bladder Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Solid Cancer 1Ovarian Neoplasms 1Melanoma 1Head and Neck Neoplasms 1HER2-positive Gastric Cancer 1Fallopian Tube Neoplasms 1Esophageal Neoplasms 1Colorectal Neoplasms 1Cholangiocarcinoma 1Carcinoma, Renal Cell 1Carcinoma, Ovarian Epithelial 1Biliary Tract Neoplasms 1Advanced Gastric or EGJ Cancer 1Adenocarcinoma of the Oesophagus 1Adenocarcinoma Of Esophagus 1Adenocarcinoma 1

Interventions

Gemcitabine 7Cisplatin 6durvalumab 5pembrolizumab 4gemcitabine-oxaliplatin regimen 3S 1 (combination) 3Carboplatin 3Trastuzumab 2Paclitaxel 2Capecitabine 2tucatinib 1tremelimumab 1merestinib 1irinotecan sucrosofate 1envafolimab 1Tegafur 1Ramucirumab 1Radiation 1Psilocybin 1Poly(ADP-ribose) Polymerase Inhibitors 1Pemetrexed 1Oxaliplatin 1Nivolumab 1Leucovorin 1Itraconazole 1Immune Checkpoint Inhibitors 1High-Throughput Nucleotide Sequencing 1Fulvestrant 1Fluorouracil 1Drug Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Biliary Tract Neoplasms × Ramucirumab × Clear all
NCT02711553 2025-08-03

A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer

Eli Lilly and Company

Phase 2 Active not recruiting
309 enrolled 22 charts
Gastrointestinal

Biliary Tract Neoplasms, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡